Search

Your search keyword '"Ang, Yeng"' showing total 285 results

Search Constraints

Start Over You searched for: Author "Ang, Yeng" Remove constraint Author: "Ang, Yeng"
285 results on '"Ang, Yeng"'

Search Results

102. The relevance and implications of signet-ring cell adenocarcinoma of the oesophagus

103. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus.

104. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus

105. Radiofrequency Ablation and Endoscopic Mucosal Resection for Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma: Outcomes of the UK National Halo RFA Registry

106. 283 Patients Undergoing Radiofrequency Ablation (RFA) for Barrett's Related Neoplasia Have Improved Outcomes With Decreasing Length's of Baseline Barrett's Eosophagus (BE) and Increasing Number of RFA Sessions

115. The pitfalls of bedside glucometers

116. The TNF region in celiac disease

121. Sex differences in oncogenic mutational processes

122. Polymorphisms Near TBX5 and GDF7 Are Associated With Increased Risk for Barrett’s Esophagus

123. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

124. Sex differences in oncogenic mutational processes

125. Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus

126. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

127. Pan-cancer analysis of whole genomes

128. FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas

129. Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma

130. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

131. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

132. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance

133. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance

134. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance

135. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance

136. The burden of Barrett's oesophagus

137. Understanding the regulatory chromatin landscape of oesophageal adenocarcinoma

141. Chromatin accessibility reveals regulatory pathways in oesophageal adenocarcinoma

142. Novel FOXM1 transcription factor target genes in oesophageal cancer

143. The FOXM1-PLK1 axis in oesophageal and gastric adenocarcinoma

144. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

145. Author Correction: Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.

146. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

147. Development and validation of a novel Barrett's oesophagus patient reported outcome measure (B-PROM).

148. Barrett's oesophagus with indefinite for dysplasia shows high rates of prevalent and incident neoplasia in a UK multicentre cohort.

149. Dedicated service for Barrett's oesophagus surveillance endoscopy yields higher dysplasia detection and guideline adherence in a non-tertiary setting in the UK: a 5-year comparative cohort study.

150. Quality of life measures in dysplastic Barrett's oesophagus are comparable to patients with non-dysplastic Barrett's oesophagus and do not improve after endoscopic therapy.

Catalog

Books, media, physical & digital resources